Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: drug prices

Lowest Price, Highest Risk? New Drug Policy’s Potential Effect on Rheumatology

From the College  |  August 11, 2025

On July 31, President Trump sent formal letters to the CEOs of 17 major pharmaceutical companies, laying out several requirements the companies must meet within 60 days or face unspecified consequences. These include Most-Favored-Nation pricing for Medicare, Medicaid and private markets.

Filed under:Legal Updates Tagged with:drug pricingMost Favored Nation

Rheumatology Could Face New Challenges Under Drug Tariff Reforms

From the College  |  August 11, 2025

A 15% tariff on all European Union exports, including pharmaceuticals, went into effect on Aug. 7. The tariff could impact the cost of providing care, patient access to therapies and drug research and development.

Filed under:Legal Updates Tagged with:drug prices

ACR Leaders Discuss Rheumatology Medications at Medicare Drug Price Negotiation Town Hall

From the College  |  May 2, 2025

On April 30, Rebecca Shepherd, MD, MBA, and Amanda Myers, MD, represented rheumatology in a live town hall on the Medicare Drug Price Negotiation Program, describing the benefits of apremilast and nintedanib for patients with rheumatic disease.

Filed under:InsuranceLegislation & Advocacy Tagged with:Advocacydrug pricesMedicare Drug Price Negotiation

ACR Expresses Concerns with MedPAC’s Drug Pricing Recommendations

From the College  |  May 9, 2023

In April, the Medicare Payment Advisory Committee voted to recommend a change in the add-on payment for Part B drugs, including reducing payment for more expensive drugs. The ACR sent a letter to MedPAC expressing concerns about the significant impacts such policies would have on rheumatologists.

Filed under:Legislation & Advocacy Tagged with:ACR advocacydrug pricingMedicare Part B drugs

CMS Announces Timeline for Drug Negotiations

From the College  |  January 20, 2023

This month, the CMS will begin steps to develop a drug pricing negotiation process as allowed by the Inflation Reduction Act. The ACR plans to participate in public comment opportunities.

Filed under:Legislation & Advocacy Tagged with:ACR advocacyCenters for Medicare & Medicaid Services (CMS)drug price negotiation

How the U.S. Will Set Up New Medicare Drug Price Talks

Ahmed Aboulenein  |  September 6, 2022

WASHINGTON—The U.S. government will soon begin hiring experts and collecting the data needed to launch direct negotiations over prescription drug prices for older and disabled people, a top Biden administration official told Reuters. President Joe Biden last week signed into law the Inflation Reduction Act, introducing new policies to tackle climate change, taxes and the…

Filed under:Drug UpdatesLegislation & Advocacy Tagged with:Centers for Medicare & Medicaid Services (CMS)drug pricingInflation Reduction ActpolicyU.S. Centers for Medicare and Medicaid Services (CMS)

Florida Law Puts Drug Pricing by Pharmacy Benefit Managers Under a Microscope Once Again

Catherine Kolonko  |  August 8, 2022

As of July 1, a Florida bill increases oversight of pharmacy benefit managers and offers some protection for pharmacies. However, the legislation has limited effects on patients and providers, highlighting the need for additional reform.

Filed under:Legislation & Advocacy Tagged with:Floridapharmacy benefit managers (PBMs)state legislation

Colchicine: An Ancient Drug with Modern Uses

Ibrahem Salloum, MD, & Deepan S. Dalal, MD, MPH  |  August 11, 2021

Discovered more than 3,000 years ago, colchicine is one of the oldest drugs still in use today. Like most old remedies, colchicine is a chemical substance found in many plants, most notably in colchicum autumnale, known as wild saffron or autumn crocus. It was mentioned in the oldest Egyptian medical text, Ebers Papyrus (circa 1550…

Filed under:ConditionsDrug UpdatesGout and Crystalline Arthritis Tagged with:anti-inflammatoryColchicinedrug treatmentGoutinflammation

Executive Order Targets Prescription Drugs & Health Insurance to Promote Competition

Natasha Yetman  |  July 19, 2021

On July 9, U.S. President Joe Biden issued an Executive Order designed to promote competition in the U.S. economy. The order includes 72 initiatives related to various aspects of the economy, including prescription drugs and health insurance.1 For prescription drugs, Americans pay more than 2.5 times as much for the same prescription drugs as patients…

Filed under:Drug UpdatesLegislation & AdvocacyProfessional Topics Tagged with:Biosimilarscostsdrug pricesexecutive orderHealth Insurance

High Cost of Specialty Drugs Demands Action

Mary Beth Nierengarten  |  July 6, 2021

Amid rising drug costs and the growing influence of pharmacy benefit managers on patient care decisions, physicians are increasingly called upon to advocate for affordable, evidence-based treatments for their patients.

Filed under:Legislation & AdvocacyPractice Support Tagged with:drug pricingpharmacy benefit managers (PBMs)

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 25
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences